NPPA revises price of Coronary Stents; Check out Details

New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), has revised the ceiling price of Coronary Stents. With this, the prices of cardiac stents will increase by 4.2% from April 1,2019.

With the move Price of Bare Metal Stents have been increased to Rs 8,261 from earlier Rs 7,660,while the price of Drug Eluting Stents (DES) including metallic DES and Bioresorbable Vascular Scaffold (BVS)/ Biodegradable Stents has been increased from Rs 27,890 to Rs 30,080

These prices are exclusive of GST.

Considering the Wholesale Price Index (WPI) @ 4.2662 per cent for the year 2018 over 2017, NPPA has decided to revise the ceiling prices of Coronary Stents as mentioned in column no. (4) in the table below, exclusive of Goods and Services Tax as applicable. The notice detail reads;

Sl No	Coronary Stents ( Sl No. 31 in Schedule-I of the DPCO, 2013)	Unit (in Number)	Ceiling Price (in Rs.)
(1)	(2)	(3)	(4)
1	Bare Metal Stents	1	8,261
2	Drug Eluting Stents (DES) including metallic DES and Bioresorbable Vascular Scaffold (BVS)/ Biodegradable Stents	1	30,080

Tye notice further adds;

• All the existing manufacturers/importers of Coronary Stents having MRP lower than the ceiling price specified in column (4) in the above table (plus Goods and Services Taxes as applicable, if any), may revise the existing MRP of Coronary Stent, on the basis of WPI @ 4.2662% for year 2018 in accordance with Paragraph 16(2) of DPCO, 2013, read with Para 13(2) of DPCO, 2013.

• The manufacturers/importers of Coronary Stents may add Goods and Services Taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (4) of the aforesaid table.

• As per Para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer/importers, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

• The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.

Also Read: Setback to Meril Lifesciences MeRess100: NPPA refuses to give relief of price cap exemption for the biodegradable stent